Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

• Adverse effects in over 20% of patients combined camizestrant with CDK4/6 inhibitors.
• The study involves women with ER+, HER2− advanced breast cancer receiving treatment.
• Analysis of adverse outcomes utilized data from SERENA-1 trial, focusing on AE profiles.
• Highlights importance of understanding adverse effects for better therapeutic strategies.